Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516476 · ClinicalTrials.gov registry record · Phase 2
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01516476 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 2 participants.
The verdict
NCT01516476, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.
Interventions
- DRUG Placebo
- DRUG liraglutide
- DRUG RO6807952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01516476
The ClinicalTrials.gov registry entry for NCT01516476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01516476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01516476 about?
NCT01516476 is a clinical study titled "Study of RO6807952 in Patients With Diabetes Mellitus Type 2". This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The ant...
What is the current status of trial NCT01516476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01516476?
The interventions under investigation include: Placebo (DRUG), liraglutide (DRUG), RO6807952 (DRUG).
Who is sponsoring clinical trial NCT01516476?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.